Meta-Analysis Based on ‘GRADE’ Method: Low-to-Moderate Evidence Ivermectin Can Help Treat COVID-19

Meta-Analysis Based on ‘GRADE’ Method Low-to-Moderate Evidence Ivermectin Can Help Treat COVID-19

The ivermectin debate intensifies around the globe as an overwhelming majority of the 40+ studies now worldwide demonstrate positive evidence, yet one recent study yielding no statistically significant results in Colombia certainly got the attention of CNN and the New York Times, both seemingly pouncing on the declaration that the economical, generic drug just doesn’t work according to the study results. Several experts have pointed out the study’s flaws. But why didn’t these news agencies at least follow the National Institute of Health (NIH) lead and mention some of the other studies as they have here? Bias could be a factor, as generally a confluence of societal elements evidence similar behavior. Recently, a group of researchers out of the United Kingdom also may have experienced a form of bias, as they were on track for acceptance with Lancet Respiratory Medicine having only to be told last minute they didn’t have sufficient data. Led by corresponding authors Andrew Bryant and Theresa A. Lawrie, the group of authors assessed whether the repurposed medicine could possibly have a role in helping treat patients infected with SARS-CoV-2, the virus behind COVID-19.  While ivermect...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee